Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies

Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to...

Full description

Bibliographic Details
Main Authors: Joseph M. Rocco, Lindsey B. Rosen, Gloria H. Hong, Jennifer Treat, Samantha Kreuzburg, Steven M. Holland, Christa S. Zerbe
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Journal of Translational Autoimmunity
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589909021000228

Similar Items